Table 2. Demographic characteristics of study subjects stratified based on genetic subgroup.

	MAPT	PGRN	C9ORF72	Overall
No. of patients: Frequency (%) A	166 (44.1)	119 (31.7)	91 (24.2)	376 (100.0)
No. of patients per study: mean (min, max) B	7.2 (2.0, 25.0)	10.0 (2.0, 34.0)	8.3 (2.0, 40.0)	8.6 (2.0, 40.0)
Age at onset: Mean years (min, max) C	45.8 (28.0, 63.5)	59.6 (54.8, 68.5)	54.7 (42.3, 70.5)	51.7 (28.0, 70.5)
Disease duration: Mean years (min, max) D	6.5 (0.7, 16.0)	6.9 (4.9, 10.0)	8.0 (2.1, 16.2)	7.1 (0.7, 16.2)
Proportion of males: % (95% CI) E	50.7 (38.0–63.4)	42.7 (31.8–54.0)	41.7 (25.1–59.3)	45.7 (37.9–53.7)

^A Fischer’s exact test: p = 0.315, therefore not statistically significant.

^B Fischer’s exact test: p = 0.196, therefore not statistically significant.

^C One-way ANOVA: p<0.001; MAPT vs. PGRN: <0.001; MAPT vs. C9ORF72: 0.024; PGRN vs. C9ORF72: 0.126.

^D One-way ANOVA: p = 0.860, therefore not statistically significant.

^E Estimates from random-effects meta-analyses.